Respiratory

Previous studies have revealed a potential connection between chronic inflammatory conditions and the predisposition of chronic obstructive pulmonary disease (COPD), and a new study has found that patients with rheumatoid arthritis (RA) are associated with a greater risk of COPD hospitalization compared to the general population.

New high-risk groups of patients with chronic obstructive pulmonary disease according to GOLD 2017 were found to have more characteristics related to acute exacerbation and mortality risks.

Patients suffering from chronic obstructive pulmonary disease and their caretakers may experience symptoms of anxiety and depression that could impact their mortality, quality of life, and healthcare use.

A new analysis finds that the mortality rate from chronic respiratory diseases has risen by almost 30% between 1980 and 2014 in the United States, and that data reflect significant differences in death rates across counties and regions.

The reduced mortality risk was not seen in patients who did not have diabetes before surgery. But in those who did, the results were dramatic.

A JAMA study has found that patients with chronic obstructive pulmonary disease (COPD) who received noninvasive ventilation in addition to home oxygen therapy went longer without being readmitted to the hospital or dying than those who received only home oxygen therapy.

For patients with chronic obstructive pulmonary disease (COPD), catching a cold is often more than just an annoyance; their risk of experiencing COPD symptom exacerbation rises 30-fold when they exhibit signs of a cold.

Weill Cornell Medicine and Boehringer Ingelheim have announced a collaboration that will investigate novel approaches to treating chronic respiratory disease.

EBRC takes a special look at Smoking and Health, the 1964 report to the Surgeon General that forever changed how this country thought about cigarettes, on the eve of its 50th anniversary.

A few weeks ago, Novo Nordisk ($NVO) said it had lost Express Scripts' business on two of its top drugs, Victoza and NovoLog. Well, that was just part of the action at the pharmacy benefits manager.